CLINICAL TRIALS PROFILE FOR ESMOLOL HYDROCHLORIDE

All Clinical Trials for esmolol hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	National Health and Medical Research Council, Australia	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	The George Institute	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.
NCT00302692 ↗	Use of Beta Blockers in Elderly Trauma Patients	Unknown status	American Heart Association	Phase 2	2005-12-01	Advances in medical care have increased the proportion of elderly Americans and enabled them to remain more physically active. This has resulted in an unprecedented increase in the number of geriatric patients admitted to trauma centers. The elderly constitute 23% of trauma center admissions, but 36% of all trauma deaths. This disproportionately high mortality is attributable to a higher prevalence of pre-existing conditions, particularly, cardiac disease. Multi-system injuries result in critical cardiac stress. Although beta-blockade has been shown to decrease morbidity and mortality in patients at risk for myocardial infarction after elective surgery, their use in trauma patients with potential underlying cardiac disease has not been previously studied. We hypothesize that routine administration of beta-blockers after resuscitation will reduce morbidity and mortality in elderly trauma patients with, or at risk for, underlying cardiac disease. This study is a randomized, prospective clinical trial. One cohort will receive routine trauma intensive care, and the other, the same care plus beta-blockade after completion of resuscitation. The primary outcome will be mortality. Secondary outcomes include MI, length of stay, organ dysfunction, cardiac, and other complications. Changes in outcome may not be due to reduction in myocardial oxygen demand and heart rate. Laboratory studies demonstrate that circulating inflammatory cytokines contribute to cardiac risk in trauma patients, and their production is influenced by adrenergic stimulation. We will measure circulating IL-6, TNF alpha, IL-1beta, and measure NF-kB and p38 MAP kinase activation in peripheral blood leukocytes, and determine the effect of beta-blockade on the production of these inflammatory markers. Finally, the wide variation in patient response to beta-blockers is attributed to genetic variability in the adrenergic receptor. Therefore, we will identify single nucleotide polymorphisms (SNPS) within the beta-adrenergic receptor, and determine their effects on mortality and response to beta-blockade. This study will provide the first randomized, prospective trial designed to reduce morbidity and mortality in elderly trauma patients at risk for cardiac disease. The laboratory and genetic component will provide additional insights that may explain treatment effects, lead to new therapeutic strategies, and have the potential to lead to additional areas of investigation.
NCT00302692 ↗	Use of Beta Blockers in Elderly Trauma Patients	Unknown status	University of Texas Southwestern Medical Center	Phase 2	2005-12-01	Advances in medical care have increased the proportion of elderly Americans and enabled them to remain more physically active. This has resulted in an unprecedented increase in the number of geriatric patients admitted to trauma centers. The elderly constitute 23% of trauma center admissions, but 36% of all trauma deaths. This disproportionately high mortality is attributable to a higher prevalence of pre-existing conditions, particularly, cardiac disease. Multi-system injuries result in critical cardiac stress. Although beta-blockade has been shown to decrease morbidity and mortality in patients at risk for myocardial infarction after elective surgery, their use in trauma patients with potential underlying cardiac disease has not been previously studied. We hypothesize that routine administration of beta-blockers after resuscitation will reduce morbidity and mortality in elderly trauma patients with, or at risk for, underlying cardiac disease. This study is a randomized, prospective clinical trial. One cohort will receive routine trauma intensive care, and the other, the same care plus beta-blockade after completion of resuscitation. The primary outcome will be mortality. Secondary outcomes include MI, length of stay, organ dysfunction, cardiac, and other complications. Changes in outcome may not be due to reduction in myocardial oxygen demand and heart rate. Laboratory studies demonstrate that circulating inflammatory cytokines contribute to cardiac risk in trauma patients, and their production is influenced by adrenergic stimulation. We will measure circulating IL-6, TNF alpha, IL-1beta, and measure NF-kB and p38 MAP kinase activation in peripheral blood leukocytes, and determine the effect of beta-blockade on the production of these inflammatory markers. Finally, the wide variation in patient response to beta-blockers is attributed to genetic variability in the adrenergic receptor. Therefore, we will identify single nucleotide polymorphisms (SNPS) within the beta-adrenergic receptor, and determine their effects on mortality and response to beta-blockade. This study will provide the first randomized, prospective trial designed to reduce morbidity and mortality in elderly trauma patients at risk for cardiac disease. The laboratory and genetic component will provide additional insights that may explain treatment effects, lead to new therapeutic strategies, and have the potential to lead to additional areas of investigation.
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	PDL BioPharma, Inc.	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.

Clinical Trial Conditions for esmolol hydrochloride

Condition Name

Condition Name for esmolol hydrochloride
Intervention	Trials
Septic Shock	10
Hypertension	6
Postoperative Pain	6
Anesthesia	6

Condition MeSH

Condition MeSH for esmolol hydrochloride
Intervention	Trials
Shock, Septic	12
Shock	12
Pain, Postoperative	9
Tachycardia	6

Clinical Trial Locations for esmolol hydrochloride

Trials by Country

Trials by Country for esmolol hydrochloride
Location	Trials
United States	28
China	26
Egypt	17
Brazil	10
France	7

Trials by US State

Trials by US State for esmolol hydrochloride
Location	Trials
California	6
Illinois	5
Utah	2
North Carolina	2
New York	2

Clinical Trial Progress for esmolol hydrochloride

Clinical Trial Phase

Clinical Trial Phase for esmolol hydrochloride
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	2
PHASE2	2

Clinical Trial Status

Clinical Trial Status for esmolol hydrochloride
Clinical Trial Phase	Trials
Completed	47
Unknown status	25
Recruiting	25

Clinical Trial Sponsors for esmolol hydrochloride

Sponsor Name

Sponsor Name for esmolol hydrochloride
Sponsor	Trials
Ain Shams University	5
The University of Hong Kong	4
Baxter Healthcare Corporation	4

Sponsor Type

Sponsor Type for esmolol hydrochloride
Sponsor	Trials
Other	153
Industry	15
OTHER_GOV	1

Esmolol Hydrochloride: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is the current clinical-trials landscape for esmolol hydrochloride?

Esmolol hydrochloride is an established, short-acting, intravenous beta-1 selective (cardioselective) blocker used for acute control of heart rate and blood pressure in settings such as supraventricular tachycardia and perioperative tachyarrhythmias. The drug’s clinical-trial footprint is dominated by older studies and ongoing post-marketing and formulation-focused investigations rather than large, late-stage brand-new efficacy trials.

How to interpret “clinical trials update” for an established IV beta blocker For matured assets like esmolol (generic and branded versions historically), the practical read-through is:

• New trials tend to be formulation, delivery, or comparator studies rather than foundational mechanism-of-action work.
• Trial activity often shows up as small-to-midsize investigations, pharmacokinetic (PK)/pharmacodynamic (PD) endpoints, or procedure-specific studies (e.g., intraoperative hemodynamics).
• Regulatory impact usually comes from label expansions (indication or population refinements) or manufacturing/CMC improvements, not from new clinical efficacy claims.

Current state of trial visibility (high-level)

• Public clinical trial registries show sporadic new entries tied to formulations, dosing regimens, and perioperative or acute-care use cases, while the core clinical evidence base predates the current decade.
• No current pattern suggests a single dominant, global Phase 3 program that would be expected to materially re-define standard of care.

What evidence types drive adoption in acute care?

For esmolol, adoption is driven by an established profile that aligns to acute ICU and perioperative workflow constraints:

Key clinical differentiators used in practice

• Rapid onset and offset (short half-life) enabling titration and rapid reversal in hemodynamically unstable settings.
• Cardioselectivity for beta-1 receptors at clinically used dosing ranges, supporting use when rate control and hemodynamic management are both priorities.
• IV controllability that reduces the risk of prolonged beta blockade compared with longer-acting agents.

Clinical use settings that typically anchor trials

• Supraventricular tachycardia (rate control, often in acute settings)
• Perioperative tachyarrhythmias (intraoperative heart rate control, hemodynamic stability)
• Acute hypertension/tachycardia management in monitored care (where rapid titration is valuable)

Which trial categories are most likely to move the needle for esmolol commercially?

Commercially meaningful updates for esmolol generally come from one of these categories:

1. Perioperative protocol optimization

   • Comparisons versus other IV rate-control drugs (or different dosing strategies)
   • Endpoints tied to time-in-target hemodynamics and rescue medication use

2. Formulation and delivery

   • Stability improvements, packaging changes, or substitution-friendly variants aimed at supply continuity and pharmacy workflow

3. Population refinements

   • Studies addressing specific subgroups (renal impairment, elderly, or specific surgical populations), typically with PK/PD or safety endpoints

4. Operational endpoints

   • Time to titration targets, incidence of hypotension/bradycardia events, and nursing/ICU workflow metrics

What does the market look like for esmolol hydrochloride?

Esmolol’s market is shaped by its role as an acute-care IV agent and by extensive generic penetration.

Market structure

• Generic availability is high, compressing pricing and shifting competition to:
  • acquisition cost
  • reliability of supply
  • product availability by strength, packaging format, and shelf-life
  • contracting and formulary access

Demand drivers

• Hospital and acute care utilization:
  • Emergency and ICU monitoring rates
  • Surgical volume with perioperative hemodynamic monitoring
• Protocol-driven use:
  • Clinician reliance on short-acting agents for titratable control
  • Inclusion in hospital formularies for tachyarrhythmia rate control pathways
• Supply chain and contracting:
  • Pharmacy procurement cycles strongly influence weekly/monthly sales

Competitive set

Esmolol competes for the same patient-need slot as other IV rate control and hemodynamic agents, especially:

• Other beta blockers (e.g., metoprolol IV where used)
• Non-dihydropyridine calcium channel blockers (where appropriate)
• Antiarrhythmic agents depending on rhythm subtype and institutional protocols

Net market implication: esmolol behaves like a high-usage acute IV commodity with pricing pressure and purchasing power concentrated in hospital systems.

How should a forecast be built for esmolol?

For an established, largely generic drug, forecast modeling typically needs to focus on volume and contracting rather than “trial breakthrough” scenarios.

Core forecast logic for esmolol

• Base-case demand tracks:
  • hospital admissions for acute cardiology indications
  • perioperative surgical volumes
  • ICU bed occupancy trends in developed markets
• Price/mix:
  • continued generic substitution suppresses average selling price
  • product format and contract tiering determine mix shifts
• Regulatory and supply events:
  • temporary supply disruptions can cause short-term demand pulls from competing IV rate-control agents
  • normalization returns volumes to baseline

Scenario set (projection framework)

Use three scenarios:

• Base case: steady demand, modest ASP compression, stable formulary penetration.
• Downside: further ASP pressure from incremental generic entries or contract renegotiations; slight volume drag from protocol shifts away from beta blocker first-line in certain pathways.
• Upside: supply stability plus protocol reinforcement for titratable beta blockade in perioperative pathways.

What matters most for the numbers

• Units growth (dose vials or mg equivalents) usually aligns with hospital procedure and acute-care activity.
• Revenue growth is mostly a function of:
  • unit growth minus
  • ongoing ASP compression from generic substitution.

What market outlook does a clinical-trials lens support?

Given esmolol’s mature clinical positioning:

• Trials are unlikely to drive a sudden step-change in standard-of-care adoption.
• The most realistic near-term market impacts come from:
  • hospital contract wins and supply continuity
  • incremental label refinements or protocol changes supported by safety and dosing studies

Revenue and volume projection: how to interpret directionally

Because esmolol is widely generic, market projections should be read as:

• Volume trend = clinical workflow trend
• Revenue trend = volume trend minus ASP compression
• Growth pockets = perioperative and acute-care protocol reinforcement rather than new indications

Projection indicators to monitor (business checklist)

• Hospital formulary updates in perioperative tachyarrhythmia pathways
• Contract tender results for IV beta blockers
• Supply continuity (manufacturing disruptions, backorders)
• Competitive substitution rates by institution

Where are the biggest “commercial levers” in the next 3 to 5 years?

1. Tender wins in hospital systems
   • Esmolol’s buyer behavior is contract-driven.
2. Product supply reliability
   • Short stock can temporarily reroute protocols; recovery can be incomplete if alternate pathways embed.
3. Education tied to protocol use
   • Standard order sets and perioperative checklists determine usage frequency.
4. Safety management protocols
   • Institutions adopt beta blockers when hypotension/bradycardia mitigation protocols exist and are easy to implement.

Key Takeaways

• Esmolol hydrochloride sits in an established, IV acute-care category where new clinical trials tend to be incremental (protocol, dosing, PK/PD, formulation) rather than transformative Phase 3 efficacy work.
• Market dynamics are dominated by generic penetration, making contracting, supply continuity, and hospital protocol adherence the main revenue drivers.
• Forecasting should be framed around volume (hospital workflow) and ASP compression (generic competition) rather than trial-driven re-rating.

FAQs

1) Is esmolol’s clinical pipeline likely to change its standard use?

Current trial patterns for established IV beta blockers typically support protocol optimization and safety-dosing refinements rather than major standard-of-care shifts.

2) What endpoints matter most in trials for esmolol-like agents?

Clinically relevant titratability endpoints include time to target heart rate or blood pressure, rescue medication usage, and rates of hypotension or bradycardia.

3) Why does esmolol tend to sell as a contracted hospital product?

Acute-care usage is predictable and inventory needs are operational, so hospital procurement focuses on pricing, supply reliability, and formulary status.

4) What competitive drugs most often displace esmolol in hospital formularies?

Other IV rate-control agents and institution-specific antiarrhythmic strategies can displace esmolol depending on rhythm subtype and protocol.

5) How should investors think about market growth for generic esmolol?

Growth is mostly volume-driven with revenue constrained by ASP compression; upside typically comes from share gains in procurement and supply stability, not from breakthrough indications.

References

[1] U.S. National Library of Medicine. “Esmolol Hydrochloride.” ClinicalTrials.gov. https://clinicaltrials.gov/
[2] FDA. Drug safety and labeling resources (esmolol hydrochloride-related labeling documents via Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification resources for beta blockers. https://www.whocc.no/